This bill, titled the Responsibility in Drug Advertising Act of 2025, aims to significantly amend the Federal Food, Drug, and Cosmetic Act by imposing new restrictions on direct-to-consumer drug advertising . Its primary provision establishes a prohibition on all forms of direct-to-consumer advertising, including on social media platforms, for any newly approved drug for a period of three years following its initial approval. A key exception allows the Secretary to grant a waiver for this prohibition during the third year, provided the drug's sponsor applies and the Secretary determines that such advertising would offer an affirmative value to public health . Furthermore, the bill grants the Secretary ongoing authority to prohibit direct-to-consumer advertising for a drug even after the initial three-year period if significant adverse health effects are identified through post-approval studies or other relevant data. The Secretary is also mandated to revise existing regulations within one year to implement these new restrictions.